Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), encompasses a spectrum of conditions ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH). Despite its prevalence, effective pharmacological treatments remain limited. Secreted proteins, known for their roles in autocrine, paracrine, and endocrine signaling, offer promising therapeutic avenues. This review synthesizes recent research on the roles of secreted proteins in MASLD pathophysiology and their potential as therapeutic targets.
Key findings from the study include:
Secreted proteins represent a promising frontier in the development of novel therapies for MASLD. Their diverse roles in metabolic regulation, coupled with their dysregulation in MASLD, underscore their therapeutic potential. However, translating preclinical findings into effective clinical treatments remains challenging. Future research should focus on optimizing the beneficial effects of secreted proteins while minimizing risks, addressing heterogeneity in MASLD, and developing more clinically relevant animal models. The work entitled “ Exploring Secreted Proteins as Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) ” was published on Protein & Cell (published on Apr. 17, 2025).
Protein & Cell
Experimental study
Not applicable
Secreted proteins in treating metabolic dysfunction-associated steatotic liver disease: from bench towards bedside
17-Apr-2025